Sun Pharmaceutical Q2 FY25 Results: Sun Pharma reported a 28% increase in consolidated net profit for Q2, reaching Rs 3,040 crore, up from Rs 2,375 crore last year. Revenue rose 9% YoY to Rs 13,291 crore, surpassing market estimates. EBITDA grew 24% YoY to Rs 3,939 crore, with a margin of 29.6%. Formulation sales in India increased 11% YoY to Rs 4,265 crore, representing 32% of total sales.
